中国临床药理学杂志2016，Vol.32Issue(6)：505-507,3.DOI:10.13699/j.cnki.1001-6821.2016.06.008
吉非替尼对非小细胞肺癌患者免疫功能的影响
Influence of gefitinib on immune function in non-small cell lung cancer patients
摘要
Abstract
Objective To evaluate the influence of gefitinib, an epider-mal growth factor receptor tyrosine kinase inhibitors ( EGFR-TKI ) , on immune function in the targeted therapy of non-small cell lung cancer ( NSCLC) patients.Methods Sixty -five patients with NSCLC were given gefitinib 250 mg, for consective 30 d.NSCLC patients’ NK and T cells changes were observed at one week before treatment and 1, 2, 6 months after treatment.After treatment, clinical efficacy and adverse re-actions of NSCLC patients were compared.Results Total effective rate was 75.38%.After 6 months treatment, CD3 +、CD4 +、CD8 +、 CD4 +/CD8 +、NK were ( 74.14 ±7.03 )%, ( 43.15 ±6.02 )%, ( 27.93 ± 4.88 )%, ( 1.98 ±0.32 ) , ( 25.34 ±3.97 )%, significantly improved compared with before treatment ( P<0.05 ) , after 6 months treatment, the interleukin-2, tumor necrosis factors-α, interferon-γ, interleu-kin-4, interleukin -5, interleukin -6 were ( 56.67 ±10.69 ), (63.71 ±10.54), (59.14 ±10.87),(27.47 ±7.12),(43.21 ±14.21), (68.98 ±12.56) ng· L-1 , significantly improved compared with before treatment ( P <0.05 ).The incidence rate of adverse reactions was 12.31%.Conclusion EGFR-TKI targeted therapy of non-small cell lung cancer can significantly improve the immune function of patients, with good clinical efficacy and low incidence of adverse reactions.关键词
表皮生长因子受体酪氨酸激酶抑制剂/非小细胞肺癌/免疫功能Key words
epidermal growth factor receptor tyrosine kinase inhibitors/non-small cell lung cancer/immune function分类
医药卫生引用本文复制引用
郭刚,李恒,郭琦,李高峰..吉非替尼对非小细胞肺癌患者免疫功能的影响[J].中国临床药理学杂志,2016,32(6):505-507,3.基金项目
云南省教育厅科学研究重点基金资助项目 （）
